BiotechTube

Mirabegron 50 MG + Placebo

Phase 1Terminated
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Achalasia

Conditions

Achalasia

Trial Timeline

Feb 15, 2018 → Dec 15, 2019

NCT ID
NCT03411252

About Mirabegron 50 MG + Placebo

Mirabegron 50 MG + Placebo is a phase 1 stage product being developed by Astellas Pharma for Achalasia. The current trial status is terminated. This product is registered under clinical trial identifier NCT03411252. Target conditions include Achalasia.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT03411252Phase 1Terminated

Competing Products

1 competing product in Achalasia

See all competitors
ProductCompanyStageHype Score
Olinciguat + Matching PlaceboCyclerion TherapeuticsPhase 2
44

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85